COMMUNIQUÉS West-GlobeNewswire

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
09/10/2026
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO ® Agreement provides Profound with [...]
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
09/10/2026
Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR MONTREAL and CHARLOTTE, N.C., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Milestone ® [...]
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
09/10/2026
Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the [...]
Nextech Unveils Agentic AI Capabilities for Patient Experience through Partnerships with Assort Health and EliseAI
09/10/2026
Specialty practices gain a choice of two leading AI patient access platforms, unveiled at AAO 2026 in New Orleans TAMPA, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nextech , a leading technology partner for specialty [...]
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
09/10/2026
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited New analyses from the ARRECTOR and DERMIS-1/2 trials [...]
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
09/10/2026
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
09/10/2026
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph. [...]
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
09/10/2026
AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of [...]
New Study Shows Cortical Disarray Measurement (CDM®) Can Reflect Microscopic Patterns of Pathology in Frontotemporal Dementia
09/10/2026
Research presented at ISFTD 2026 connects measurements from the living brain with disease patterns confirmed through postmortem analysis OXFORD, United Kingdom, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Oxford Brain Diagnostics [...]
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
09/10/2026
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg) ISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, [...]
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
09/10/2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of <130 [...]
NTG Nordic Transport Group A/S - Q3 2026 Conference Call
09/10/2026
NTG Nordic Transport Group A/S – Q3 2026 Conference Call We expect to release the Q3 2026 interim results of NTG Nordic Transport Group on the evening of November 9, 2026. A webcast and conference call will be held on [...]
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
09/10/2026
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching [...]
A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura's roginolisib
09/10/2026
First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study [...]
T·Time Launches Cash-Pay Compounded GLP-1 and GIP Injections With Flat Pricing
09/10/2026
Austin, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- T·Time Health Inc. , the telehealth brand at ttime.men, has launched cash-pay compounded injectable semaglutide and tirzepatide with one published rate regardless of [...]
TherapiAI Showcases Agentic AI Platform for Biopharma at BioJapan 2026
09/10/2026
YOKOHAMA, Japan, Oct. 09, 2026 (GLOBE NEWSWIRE) -- TherapiAI, a Taipei-based developer of AI agents for drug development and manufacturing, showcased its Biopharma AI Operating Layer at BioJapan 2026 this week as it [...]
FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
09/10/2026
FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50 [...]
Kylo Peptides Introduces Lifetime 50% Member Pricing for Peptide Research Buyers
09/10/2026
The new membership pricing program gives eligible research buyers 50% off standard pricing on qualifying Kylo Peptides research products. SHERIDAN, WYOMING, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https:// [...]
TRexBio Announces Pricing of Initial Public Offering
09/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of [...]

Pages